18-fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series

BMC Pulmonary Medicine

Eric R Houpt³  Patrice K Rehm¹  Costi D Sifri²  Tania A Thomas³  Scott K Heysell³ 

[1] Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, USA;Office of Hospital Epidemiology/Infection Prevention and Control, University of Virginia Health System, Charlottesville, USA;Division of Infectious Diseases and International Health, University of Virginia, PO Box 801337, Charlottesville, VA 29908-1337, USA

关键词: Pulmonary nodule;    Multidrug-resistant tuberculosis;    Tuberculosis;    Positron emission tomography;   

Others  :  1131209
DOI  :  10.1186/1471-2466-13-14

 received in 2012-10-12, accepted in 2013-03-15,  发布年份 2013

【 摘 要 】

Background

F-fluorodeoxyglucose positron emission tomography (FDG-PET) is increasingly used to investigate for malignancy in the evaluation of pulmonary nodules, yet both active tuberculosis (TB) and malignancy have high uptake of FDG. Definitive diagnosis of TB can be further hindered in patients without growth of the organism from sputum.

Case presentations

We describe a series of four representative cases of TB in varying disease state originally imaged by FDG-PET during evaluation for malignancy. Decisions regarding treatment for active TB in the presence of negative cultures and the evolving understanding of the spectrum of the TB disease state are discussed.

Conclusions

FDG-PET may possess a role in the diagnosis of active TB infection in settings where conventional microbiological methods are unavaiable and holds particular promise for monitoring response to therapy in cases of unsettled treatment duration such as multidrug-resistant TB or in extrapulmonary TB.

【 授权许可】

   
2013 Heysell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lillington GA, Caskey CI: Evaluation and management of solitary and multiple pulmonary nodules . Clin Chest Med 1993, 14:111-119.
• [2]El-Haddad G, Zhuang H, Gupta N, Alavi A: Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders . Semin Nucl Med 2004, 34(4):313-329.
• [3]Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C: Dual time-point FDG PET/CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area . S Afr Med J 2010, 100:598-601.
• [4]Malik K, Dedhia HV, Bishop H: Clinical utility of PET-FDG imaging in detecting malignancy in pulmonary lesions . Chest 1996, 110(suppl):95S.
• [5]Hara T, Kosaka N, Suzuki T, Kudo K, Niino H: Uptake rates of 18-Fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study . Chest 2003, 124:893-901.
• [6]Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK: Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases . Radiology 2000, 216:117-121.
• [7]Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, Ishizaki T, Fujibayashi Y, Okazawa H: Usefulness of 18 F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis . Eur J Nucl Med Mol Imaging 2009, 36:632-639.
• [8]Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S, Doucet-Populaire F, Boué F: (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response . Int J Tuberc Lung Dis 2012, 16(9):1180-1185.
• [9]Soussan M, Brillet PY, Mekinian A, Khafagy A, Nicolas P, Vessieres A, Brauner M: Patterns of pulmonary tuberculosis on FDG-PET/CT . Eur J Radiol 2012, 81(10):2872-2876.
• [10]Treglia G, MD , Taralli S, Calcagni ML, Maggi F, Giordan A, Bonomo L: Is there a role for fluorine 18-fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review . J Comput Assist Tomogr 2011, 35:387-393.
• [11]Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, Nam HY, Kim JS: Double phase 18 F-FDG PET-CT for determination of pulmonary tuberculoma activity . Eur J Nucl Med Mol Imaging 2008, 35:808-814.
• [12]Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies . Nature Reviews 2009, 7:845-855.
• [13]Lin PL, Flynn JL: Understanding latent tuberculosis: a moving target. J Immunol 2010, 185:15-22.
• [14]Via LE, Schimel D, Weiner DM: Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [18 F]2-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography . Antimicrob Agents Chemother 2012, 56(8):4391.
• [15]Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J: Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis . Lancet 2010, 375:1830-1843.
• [16]Tian G, Xiao Y, Chen B, Xia J, Guan H, Deng Q: FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis . Acta Radiologica 2010, 9:1002-1006.
• [17]Kim SJ, Kim IJ, Suh KT, Kim YK, Lee JS: Prediction of residual disease of spine infection using F-18 FDG PET/CT . Spine 2009, 34:2424-2430.
• [18]Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C: Use of 18 F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis . J Nucl Med 2011, 52:880-885.
• [19]Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK: Noninvasive pulmonary [18 F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment . Antimicrob Agents Chemother 2009, 53:4879-4884.